相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum IL-35 levels is a new candidate biomarker of cancer-related cachexia in stage IV non-small cell lung cancer
Zengxun Li et al.
THORACIC CANCER (2022)
IL-35 inhibits cell pyroptosis and attenuates cell injury in TNF-α-induced bronchial epithelial cells via p38 MAPK signaling pathway
Yanbo Wang et al.
BIOENGINEERED (2022)
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
Yencheng Chao et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2022)
Serum level of interleukin-35 as a potential prognostic factor for gastric cancer
Jin-Hua Gu et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)
Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma
X. Liu et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2021)
Correlation Analysis Among the Level of IL-35, Microvessel Density, Lymphatic Vessel Density, and Prognosis in Non-Small Cell Lung Cancer
Tenglong Zhang et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis
Meng Li et al.
EXPERIMENTAL CELL RESEARCH (2021)
The Effect of IL-35 on the Expression of Nasal Epithelial-Derived Proinflammatory Cytokines
Mingrong Nie et al.
MEDIATORS OF INFLAMMATION (2021)
A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis
Zhe Cai et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
IL-35 promotes EMT through STAT3 activation and induces MET by promoting M2 macrophage polarization in HCC
Yuan He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
Diego Kauffmann-Guerrero et al.
SCIENTIFIC REPORTS (2021)
Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
Valerio Nardone et al.
FRONTIERS IN ONCOLOGY (2021)
Interleukin 35 ameliorates myocardial ischemia-reperfusion injury by activating the gp130-STAT3 axis
Xingdi Zhou et al.
FASEB JOURNAL (2020)
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
Jeffrey C. Thompson et al.
LUNG CANCER (2020)
IL-35 Inhibited Th17 Response in Children with Allergic Rhinitis
Fengmei Xie et al.
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY (2020)
IL-35 promotes microglial M2 polarization in a rat model of diabetic neuropathic pain
Yinghai Jiang et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2020)
Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer
Yi Na Wang et al.
ONCOLOGY LETTERS (2020)
Serum IL-35 Levels Are Associated With Activity and Progression of Sarcoidosis
Zhao Mengmeng et al.
FRONTIERS IN IMMUNOLOGY (2020)
Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
Minkyung Kang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
Jialin Zhu et al.
CANCER CELL INTERNATIONAL (2020)
EMT, MET, Plasticity, and Tumor Metastasis
Basil Bakir et al.
TRENDS IN CELL BIOLOGY (2020)
Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer
Nazanin Chatrabnous et al.
CYTOKINE (2019)
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Chien-Hui Weng et al.
ONCOGENE (2019)
Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status
Koji Fukuda et al.
CANCER RESEARCH (2019)
IL-35 ameliorates collagen-induced arthritis by promoting TNF--induced apoptosis of synovial fibroblasts and stimulating M2 macrophages polarization
Mingzheng Peng et al.
FEBS JOURNAL (2019)
IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome
Chuan-jiang Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Ebi3 promotes T- and B-cell division and differentiation via STAT3
Ning Ma et al.
MOLECULAR IMMUNOLOGY (2019)
Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer
Lisanne Heim et al.
BRITISH JOURNAL OF CANCER (2019)
Comprehensive genomic and prognostic analysis of the IL-17 family genes in lung cancer
Tingting Liao et al.
MOLECULAR MEDICINE REPORTS (2019)
Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer
Jialin Zhu et al.
ONCOLOGY LETTERS (2019)
Targeting Treg cells in cancer immunotherapy
Atsushi Tanaka et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
IL-35 alleviates inflammation progression in a rat model of diabetic neuropathic pain via inhibition of JNK signaling
Yinghai Jiang et al.
JOURNAL OF INFLAMMATION-LONDON (2019)
Human placental trophoblast cells contribute to maternal-fetal tolerance through expressing IL-35 and mediating iTR35 conversion
Jia Liu et al.
NATURE COMMUNICATIONS (2019)
Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients
Ming-Xi Liu et al.
CONNECTIVE TISSUE RESEARCH (2019)
KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT
Zhiyuan Tang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2019)
Inhibition of cardiac allograft rejection in mice using interleukin-35-modified mesenchymal stem cells
Wei Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2019)
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
Liliang Xia et al.
ONCOLOGIST (2019)
Interleukin-35 as an Emerging Player in Tumor Microenvironment
Wenhua Xue et al.
JOURNAL OF CANCER (2019)
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
Jia Li Low et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Varun Sasidharan Nair et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells
Yuan Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Emerging role of IL-35 in inflammatory autoimmune diseases
Lin-Chong Su et al.
AUTOIMMUNITY REVIEWS (2018)
Interleukin 35: Inhibitory regulator in monocyte-derived dendritic cell maturation and activation
Xi Chen et al.
CYTOKINE (2018)
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy
Minan Wang et al.
FASEB JOURNAL (2018)
Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process
Fang Li et al.
ONCOLOGY REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization
Chih-Chan Lee et al.
NATURE COMMUNICATIONS (2018)
Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells
Shengnan Hao et al.
CARCINOGENESIS (2018)
IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases
Zhendong Zhu et al.
HUMAN IMMUNOLOGY (2018)
Prospects for new lung cancer treatments that target EMT signaling
Yuji Otsuki et al.
DEVELOPMENTAL DYNAMICS (2018)
IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation
Linkun Hu et al.
INFLAMMATION (2017)
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease
Malik Quasir Mahmood et al.
MEDICAL ONCOLOGY (2017)
FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer
Shucai Yang et al.
MOLECULAR CANCER (2017)
IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients
Wei Wu et al.
ONCOLOGY LETTERS (2017)
KDM3A promotes inhibitory cytokines secretion by participating in TLR4 regulation of Foxp3 transcription in lung adenocarcinoma cells
Yinan Li et al.
ONCOLOGY LETTERS (2017)
IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease
Ivy M. Dambuza et al.
NATURE COMMUNICATIONS (2017)
Progress and prospects of early detection in lung cancer
Sean Blandin Knight et al.
OPEN BIOLOGY (2017)
Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells
An-Fu Lee et al.
PLOS ONE (2017)
The paradox of Th17 cell functions in tumor immunity
Zahra Asadzadeh et al.
CELLULAR IMMUNOLOGY (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
WNT signaling - lung cancer is no exception
Judit Rapp et al.
RESPIRATORY RESEARCH (2017)
Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer
Nikolaos Tsoukalas et al.
ANTICANCER RESEARCH (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer
Zhonghua Zhao et al.
CYTOKINE (2017)
Interleukin-17 potently increases non-small cell lung cancer growth
Lei Wei et al.
MOLECULAR MEDICINE REPORTS (2016)
Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
Yi-Peng Fu et al.
BRITISH JOURNAL OF CANCER (2016)
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
Zhenyu Zhong et al.
CELL (2016)
Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma
Xiangting Qiu et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Immune checkpoint therapy for non-small-cell lung cancer: an update
Bing Xia et al.
IMMUNOTHERAPY (2016)
IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis
Junfeng Zhang et al.
JOURNAL OF IMMUNOLOGY (2016)
Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
Jingwei Liu et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Epstein-Barr Virus-Induced Gene 3 (EBI3) Blocking Leads to Induce Antitumor Cytotoxic T Lymphocyte Response and Suppress Tumor Growth in Colorectal Cancer by Bidirectional Reciprocal-Regulation STAT3 Signaling Pathway
Yanfang Liang et al.
MEDIATORS OF INFLAMMATION (2016)
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response
C. Botta et al.
CELL DEATH & DISEASE (2016)
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
E. C. Martino et al.
CELL DEATH DISCOVERY (2016)
Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC
S. A. Almatroodi et al.
CANCER MICROENVIRONMENT (2016)
Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells
J. Dong et al.
ALLERGY (2015)
Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer
Bo Pan et al.
BIOMARKERS (2015)
Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies
Yang Yu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer
Min-Chao Duan et al.
INFLAMMATION (2015)
Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts
Qianshan Tao et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma
Juan Liao et al.
MOLECULAR MEDICINE REPORTS (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Th17 Cell Plasticity and Functions in Cancer Immunity
Leslie Guery et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Differential roles of STAT3 in the initiation and growth of lung cancer
J. Zhou et al.
ONCOGENE (2015)
Detection and significance of TregFoxP3+ and Th17 cells in peripheral blood of non-small cell lung cancer patients
Sha Li et al.
ARCHIVES OF MEDICAL SCIENCE (2014)
Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer
Chunhua Xu et al.
BIOMARKERS (2014)
IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor
Michael B. Nicholl et al.
CYTOKINE (2014)
Circulating IL-35 in pancreatic ductal adenocarcinoma patients
Peng Jin et al.
HUMAN IMMUNOLOGY (2014)
Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
Akihiro Kogita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
David J. Stewart
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Mathematical Modeling of Interleukin-35 Promoting Tumor Growth and Angiogenesis
Kang-Ling Liao et al.
PLOS ONE (2014)
Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer
Jun Li et al.
ONCOLOGY LETTERS (2014)
The Treg/Th17 Paradigm in Lung Cancer
Min-Chao Duan et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
Katherine Chang et al.
CRITICAL CARE (2014)
IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells
Jun Long et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis
Zhihui Wang et al.
JOURNAL OF IMMUNOLOGY (2013)
The plasticity and stability of regulatory T cells
Shimon Sakaguchi et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Prevention of Autoimmune Diabetes by Ectopic Pancreatic β-Cell Expression of Interleukin-35
Maria Bettini et al.
DIABETES (2012)
Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer
Ting Ai et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2012)
The composition and signaling of the IL-35 receptor are unconventional
Lauren W. Collison et al.
NATURE IMMUNOLOGY (2012)
What are regulatory T cells (Treg) regulating in cancer and why?
Theresa L. Whiteside
SEMINARS IN CANCER BIOLOGY (2012)
Bacterial infection profiles in lung cancer patients with febrile neutropenia
Jean-Philippe Lanoix et al.
BMC INFECTIOUS DISEASES (2011)
Effects of IL-17A on the occurrence of lung adenocarcinoma
Ying Li et al.
CANCER BIOLOGY & THERAPY (2011)
Identification of Epstein-Barr Virus-Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer
Ryohei Nishino et al.
CLINICAL CANCER RESEARCH (2011)
A dual role for the immune response in a mouse model of inflammation-associated lung cancer
Michael Dougan et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
被撤回的出版物: Cutting Edge: Human Regulatory T Cells Require IL-35 To Mediate Suppression and Infectious Tolerance (Retracted article. See vol. 191, pg. 2018, 2013)
Vandana Chaturvedi et al.
JOURNAL OF IMMUNOLOGY (2011)
Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
Richeng Jiang et al.
MOLECULAR DIAGNOSIS & THERAPY (2011)
The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN
Yan-Ying Wang et al.
TARGETED ONCOLOGY (2011)
Differentiation of Effector CD4 T Cell Populations
Jinfang Zhu et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development
R. Kesselring et al.
BRITISH JOURNAL OF CANCER (2010)
Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells
Xi Chen et al.
CANCER SCIENCE (2010)
IL-35-mediated induction of a potent regulatory T cell population
Lauren W. Collison et al.
NATURE IMMUNOLOGY (2010)
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Natalia Martin-Orozco et al.
IMMUNITY (2009)
Regulatory T Cell Suppression Is Potentiated by Target T Cells in a Cell Contact, IL-35-and IL-10-Dependent Manner
Lauren W. Collison et al.
JOURNAL OF IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Epithelial to mesenchymal transition in head and neck squamous carcinoma - Association of src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features
Mahitosh Mandal et al.
CANCER (2008)
Wnt1 overexpression promotes tumour progression in non-small cell lung cancer
Cheng-Long Huang et al.
EUROPEAN JOURNAL OF CANCER (2008)
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Shawn D. Blackburn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells
Wanda Niedbala et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer
C. Y. Ngan et al.
BRITISH JOURNAL OF CANCER (2007)
Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors
Egbert Baumgart et al.
CLINICAL CANCER RESEARCH (2007)
The role of epithelial-mesenchymal transition in cancer pathology
Marcello Guarino et al.
PATHOLOGY (2007)
Wnt/β-catenin signaling in development and disease
Hans Clevers
CELL (2006)
The epithelial-mesenchymal transition: new insights in signaling, development, and disease
JM Lee et al.
JOURNAL OF CELL BIOLOGY (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis
M Numasaki et al.
JOURNAL OF IMMUNOLOGY (2005)
Wnt signalling regulates adult hippocampal neurogenesis
DC Lie et al.
NATURE (2005)
Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells
WZ Wei et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Dissociation between T helper type 1 and type 2 differentiation and cytokine production in tumor-infiltrating lymphocytes in patients with lung cancer
N Ito et al.
SURGERY TODAY (2001)
分享论文
